Cargando…

A Patient-Centered Evaluation of Meaningful Change on the 32-Item Motor Function Measure in Spinal Muscular Atrophy Using Qualitative and Quantitative Data

The 32-item Motor Function Measure (MFM32) is an assessment of motor function used to evaluate fine and gross motor ability in patients with neuromuscular disorders, including spinal muscular atrophy (SMA). Reliability and validity of the MFM32 have been documented in individuals with SMA. Through s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duong, Tina, Staunton, Hannah, Braid, Jessica, Barriere, Aurelie, Trzaskoma, Ben, Gao, Ling, Willgoss, Tom, Cruz, Rosangel, Gusset, Nicole, Gorni, Ksenija, Randhawa, Sharan, Yang, Lida, Vuillerot, Carole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802297/ https://www.ncbi.nlm.nih.gov/pubmed/35111124 http://dx.doi.org/10.3389/fneur.2021.770423

Ejemplares similares

Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers’ perspective: a two-part study
por: Duong, Tina, et al.
Publicado: (2021)

Correction to: Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers’ perspective: a two-part study
por: Duong, Tina, et al.
Publicado: (2021)

Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy
por: Trundell, Dylan, et al.
Publicado: (2020)

Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy
por: Trundell, Dylan, et al.
Publicado: (2020)

Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures
por: Aponte Ribero, Valerie, et al.
Publicado: (2023)

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)

The need for evidence‐based treatment decisions in spinal muscular atrophy type 0
por: Erbas, Yasemin, et al.
Publicado: (2021)

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
por: Pera, Maria C., et al.
Publicado: (2017)

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
por: Baranello, Giovanni, et al.
Publicado: (2021)

Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study
por: Annoussamy, Mélanie, et al.
Publicado: (2020)

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
por: Lo, Siu Hing, et al.
Publicado: (2021)

Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)
por: Kitchen, Helen, et al.
Publicado: (2021)

A qualitative study of perceptions of meaningful change in spinal muscular atrophy
por: McGraw, Sarah, et al.
Publicado: (2017)

Economic burden of spinal muscular atrophy: an analysis of claims data
por: Belter, Lisa, et al.
Publicado: (2020)

Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey
por: Belter, Lisa, et al.
Publicado: (2020)

Estimating meaningful thresholds for multi-item questionnaires using item response theory
por: Terluin, Berend, et al.
Publicado: (2023)

Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Analysis of 29 Items of the Meaningful Activity Participation Assessment-Meaningful Scale Through Rasch Analysis
por: Nam, Sanghun, et al.
Publicado: (2021)

Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States
por: Darras, Basil T., et al.
Publicado: (2022)

Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)

Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
por: Cances, Claude, et al.
Publicado: (2022)

Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA)
por: Curry, Mary, et al.
Publicado: (2021)

Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps
por: Braid, Jessica, et al.
Publicado: (2023)

Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
por: Sergott, Robert C., et al.
Publicado: (2020)

Establishing thresholds for meaningful within-individual change using longitudinal item response theory
por: Bjorner, Jakob Bue, et al.
Publicado: (2022)

The Twenty Item Prosopagnosia Index (PI20) provides meaningful evidence of face recognition impairment
por: Tsantani, Maria, et al.
Publicado: (2021)

Quantitative and Qualitative Exploration of Meaningful Change on the Vineland Adaptive Behavior Scales (Vineland™-II) in Children and Adolescents with Autism Without Intellectual Disability Following Participation in a Clinical Trial
por: Clinch, Susanne, et al.
Publicado: (2023)

Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative?
por: Montes, Jacqueline, et al.
Publicado: (2015)

The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy
por: Belter, Lisa, et al.
Publicado: (2021)

Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study
por: Chabanon, Aurélie, et al.
Publicado: (2018)

Loss of DARPP-32 and calbindin in multiple system atrophy
por: Hayakawa, Hideki, et al.
Publicado: (2013)

Validity of the 32-item Hypomania Checklist (HCL-32) in a clinical sample with mood disorders in China
por: Yang, Hai-chen, et al.
Publicado: (2011)

An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments
por: Staunton, Hannah, et al.
Publicado: (2019)

A link between agrin signalling and Ca(v)3.2 at the neuromuscular junction in spinal muscular atrophy
por: Delers, Perrine, et al.
Publicado: (2022)

The Concurrent Criterion Validity of the 32-Item Fitness-to-Drive Screening Measure
por: Medhizadah, Shabnam, et al.
Publicado: (2019)

Aging, Culture, and Memory for Socially Meaningful Item-Context Associations: An East-West Cross-Cultural Comparison Study
por: Yang, Lixia, et al.
Publicado: (2013)

Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine
por: Houts, Carrie R., et al.
Publicado: (2020)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Cannot write session to /tmp/vufind_sessions/sess_48ictmbkht51heqe1pah80gcbd